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Background:  Early  onset  of  persistent  otitis  media  is  a priority  issue  for Australian  Indigenous  popula-
tions.  The  objective  is to  determine  the  direct  and  short-term  impact  of one,  two  and  three  doses  of
any  pneumococcal  conjugate  vaccine  (PCV)  formulation  on  nasopharyngeal  (NP)  carriage  of  Streptococ-
cus pneumoniae  (Spn)  and  non-typeable  Haemophilus  inﬂuenzae  (NTHi),  the  otopathogens  targeted  by
current  PCVs.
Methods: We  searched  MEDLINE  (PubMed)  and CENTRAL  (Cochrane  Library)  to  29 September  2015.  We
also  scanned  reference  lists  of recent  reviews  and  contacted  authors.  We  included  randomised  controlled
trials (RCTs)  with  a PCV  schedule  commencing  ≤3  months  of age  that reported  controlled  non-cumulative
group-speciﬁc  prevalence  data  for carriage  of  Spn  or  NTHi  at age  < 12  months.  We  performed  a standard
risk  of  bias  assessment.  We  estimated  the  pooled  relative  risk  (RR)  and  95% conﬁdence  interval  (95%CI)
for  each  vaccine  dose  on NP  carriage  by meta-analysis.
Results:  We  included  16 RCTs  involving  14,776  participants.  The  PCVs  were  conjugated  to  diphtheria  toxin
CRM197,  diphtheria  toxoid,  tetanus  toxoid  or NTHi  protein  D  and varied  in  valency  (4–13).  Controls  were
non-PCVs,  placebo  or no  vaccine.  The  earliest  carriage  outcome  was  from  2  to  9 months  of  age.  Compared
to controls,  there  were  no signiﬁcant  differences  between  one  or two  doses  of  PCV  on vaccine-type  (VT)
pneumococcal  carriage  at ∼4  and  ∼6  months  respectively.  However,  VT carriage  was  signiﬁcantly  lower  at
∼7 months  RR  0.67  95%CI  0.56–0.81  from  9 studies  and  7613  infants  and  non-vaccine  type  (NVT)  carriage
was  higher  RR 1.23  95%CI  1.09–1.40  from  8 studies  and  5861  infants.  No  impact  on  overall  pneumococcal
or  NTHi  carriage  was found.
Conclusions:  The  primary  PCV  schedule  had  no  signiﬁcant  short-term  impact  on  overall  pneumococcal  or
NTHi  NP carriage  and  a limited  impact  on VT  pneumococcal  carriage  before  the  third  dose.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Carriage of bacteria in the nasopharynx can lead to invasive
isease, pneumonia and otitis media [1]. In remote Aboriginal
ommunities in Australia, almost all babies have otitis media
ithin weeks of birth following nasopharyngeal (NP) colonisa-
ion with both Streptococcus pneumoniae (Spn) and non-typeable
aemophilus inﬂuenzae (NTHi), which increases the risk of otitis
Abbreviations: RCT, randomised controlled trial; PCV, pneumococcal conjugate
accine; Spn, Streptoccoccus pneumoniae; NTHi, non-typeable Haemophilus inﬂuen-
ae;  NP, nasopharyngeal; VT, vaccine-type; NVT, non-vaccine-type.
∗ Corresponding author. Tel.: +61 08 89468560/ +61 0408086291;
ax: +61 08 8927 5187.
E-mail address: amanda.leach@menzies.edu.au (A.J. Leach).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.048
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
media 33-fold [2]. In one remote community, 72% of Aboriginal
children developed otitis media by two  months of age [3]. Vac-
cines that have an early and direct impact on acquisition or density
of NP carriage, following early ﬁrst dose or accelerated sched-
ules, are needed. The risk of conductive hearing loss, impaired
language development and educational disadvantage [4] through-
out formative years may  be partly addressed by vaccination. For
developing countries, where NP carriage also occurs early in life
[5], reduced dose schedules that are protective early could provide
an affordable option. Huebner et al. [6] has indicated that an
immune response (IgG > 0.15 g/mL) is mounted to all 9 serotypes
after a single dose of vaccine in 70% of children at 10 weeks of
age. However, efﬁcacy for carriage prevention was not assessed
at this age. Indirect protection of non-vaccinees occurs follow-
ing direct impacts of vaccination on NP carriage in vaccinees
[7,8].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Three systematic reviews [9–11] have been published recently
n the impact of PCVs on NP carriage. Fleming-Dutra’s [9] search
o 2010 assessed vaccine-type (VT) carriage following two  or
hree-dose primary and booster schedules. Randomised and non-
andomised studies were included and results were not statistically
ombined. Both two and three-dose schedules reduced VT pneu-
ococcal carriage. Non-vaccine type (NVT) replacement and post
ingle dose outcomes were not reported. Scott’s [10] search to
010 focused on immunogenicity and included two  studies for the
arriage component. No difference between two and three-dose
chedules was found at six months of age. Davis’s [11] search to
005 examined the indirect effect on non-target populations. A
ontemporaneous relationship between VT invasive pneumococ-
al disease and VT carriage was found, supporting the inclusion of
P carriage in vaccine licensure processes.
Currently, the impact of each dose of the primary PCV sched-
le on NP carriage, with the pooled estimate derived solely from
andomised controlled trials (RCT), is not known. Our aim was to
eview RCTs of PCVs to determine whether infants receiving 1, 2 or
 doses of PCV in a primary schedule commencing ≤3 months of
ge have reduced NP carriage of Spn and NTHi in the short term.
. Methods
.1. Eligibility criteria
We  used the following eligibility criteria: (a) RCTs of any PCV
chedule commencing ≤ 3 months of age; (b) NP carriage was mea-
ured <12 months of age, after at least one dose of PCV and prior
o the booster; and (c) controlled non-cumulative group-speciﬁc
revalence data for carriage of Spn and/or NTHi.
.2. Information sources
We  searched the MEDLINE (PubMed) and CENTRAL (Cochrane
ibrary) databases to 29 Sept 2015. We  also reviewed the reference
ists of recent reviews and contacted authors.
.3. Search terms
Our search strategy for MEDLINE (performed 29/09/2015)
as: (pneumococcal vaccines[mesh] AND conjugate) AND (clinical
rial[pt] OR systematic[sb]) AND (neonate[mesh] OR infant[mesh]
R child[mesh]) AND (1990/01/01:2015/09/29 [edat]).
We used an equivalent search strategy for CENTRAL (performed
9/09/2015).
.4. Study selection
One review author [TN] manually screened the citations in three
tages: (1) titles, (2) abstract and (3) full text. Citations that failed
o meet our eligibility criteria were excluded at each stage. The
rticles that could not immediately be excluded were discussed
ith a second review author [PM or AJL].
.5. Data collection process
Two review authors [TN, AJL] independently extracted the rel-
vant data from the included studies. Where carriage data were
ggregated across scheduled visits or groups or where carriage data
ad not yet been published, we contacted the authors for raw data
r used online trial databases. 34 (2016) 703–713
2.6. Data items
The following data items were extracted from each included
paper or the primary publication of the RCT: year, author, risk of
bias items (below), study population, number of participants ran-
domised for NP carriage, randomisation age, vaccine formulation,
vaccine schedule, nasopharyngeal swab schedule and prevalence
of Spn and NTHi at the earliest time point given <12 months for
each dose comparison. We  did not extract data on acquisition or
cumulative incidence of carriage.
To extract data for meta-analysis, the following techniques were
employed. For the NP carriage denominator, we  assumed that
all children assessed at each time point also had an NP swab,
unless explicit numbers were provided. For overall, VT and NVT
Spn carriage, we  assumed that VT + NVT = overall Spn carriage. We
combined allocated groups when appropriate.
We  assumed that H. inﬂuenzae and NTHi were synonymous
across studies. Where both were given, we reported NTHi. For NTHi,
we only extracted data from the PHiD-CV10 and 11Pn-PD RCTs, as
we were interested in direct effects. We  reported pneumococcal
VT carriage as per the author’s deﬁnition. If not speciﬁed, cross-
protected serotypes were deﬁned as NVTs.
2.7. Risk of bias
We  assessed risk of bias for the methodology reported in each
included paper or the primary publication of the RCT. We  applied
the principles of the Cochrane ‘Risk of Bias’ tool. Two review
authors [TN, AJL] independently assessed each component and dis-
cussed their ﬁndings until consensus was  reached. The components
assessed were: random sequence generation; allocation conceal-
ment; blinding of participants and personnel; blinding of outcome
assessor; incomplete outcome data and selective reporting. These
components addressed risk of bias due to selection, performance,
detection, attrition and reporting. We  also assessed reporting of
baseline characteristics to address selection bias. If the informa-
tion provided was inadequate but it appeared that the component
was appropriately performed or if the author had set precedence
by performing the component appropriately in a previous trial
without explicitly reporting so in the paper [12], we deemed the
information unclear but ‘probably low’ risk of bias. Where partici-
pants and personnel were not blinded or blinding was  not explicitly
stated, clinical care such as antibiotic use may  have affected the
carriage outcome. However, we  considered this to be uncommon
and deemed these studies as ‘probably low’ risk of bias. For each
study, we also extracted information on the funding source, the
compliance with WHO  recommendations for NP carriage studies
[13,14] and the population naivety to PCV exposure. Populations
that had hosted previous pneumococcal trials but were otherwise
naïve were considered to be naïve. These study characteristics may
contribute to clinical heterogeneity but do not necessarily infer
higher risk of bias. Therefore, they were not formally included in
our risk of bias summary.
2.8. Methods of analysis
The meta-analyses were generated with Stata 14. We  pooled
relative risks using the random-effects model. For each dose com-
parison, a relative risk (RR) and 95% conﬁdence interval (95%CI)
were estimated. We  determined the associated statistical hetero-
geneity using the I2 test.2.9. Risk of bias across studies
We  used funnel plots to assess possible small study bias (includ-
ing publication bias). Plots were generated for three versus zero
accine 34 (2016) 703–713 705
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Fig. 1. Flow diagram: a systematic search for randomised controlled trials com-
paring the short-term impact of one, two and three primary doses of pneumococcalT.R. Nicholls et al. / V
ose overall, VT and NVT pneumococcal meta-analyses and the
wo versus zero dose overall pneumococcal meta-analysis. Other
ose comparisons had too few studies. To assess within study selec-
ive reporting, we used the principles of the Cochrane ‘Risk of Bias’
ool. Sensitivity analyses were done by removing studies which
ontributed high risk of bias for any component of the Cochrane’s
Risk of Bias’ tool.
. Results
.1. Study selection
A total of 16 RCTs involving 14,776 participants were included
n the systematic review and meta-analyses (Table 1) [15–30]. To
ssess study characteristics and risk of bias, the primary publication
f the RCT was also referred to for seven of the included studies
31–37]. Similarly, we referred to an additional methods paper for
ne included study [38] and the published protocol for another [27].
The MEDLINE search (Fig. 1) provided 426 citations and 12 stud-
es met  our eligibility criteria [15–23,26,29,30]. Two  of these studies
eported carriage data in online databases, ClinicalTrials.gov and
SK Clinical Trials Register [29,30].
The CENTRAL search identiﬁed no additional eligible studies.
Our manual search provided four additional studies—two of
hich [24,25] were found by reviewing reference lists of recent
eviews and one (abstract) [28] by corresponding with a senior
uthor. The fourth study is our ongoing RCT for which we analysed
he unpublished dataset [27].
.2. Study characteristics
.2.1. Participants
Study populations and the number of infants randomised for
arriage (n) varied across the included studies. Four studies took
lace in Europe; two (n = 780, 1005) took place in the Netherlands
17,19], one (n = 381) in the Czech Republic & Slovakia [22] and
ne (n = 5093) in Finland [30]. Twelve studies took place outside
urope. Four took place in Africa–two (n = 500, 300) in South Africa
25,28] and two (n = 684, 207) in the Gambia [20,24]. Three stud-
es (n = 1866, 733, 75) took place in Israel [16,18,26], one (n = 566)
n Navajo and White Mountain Apache reservations [23], one
n = 1628 infants for Spn, 1644 for NTHi) in Argentina, Panama and
olumbia [29], one (n = 552) in Fiji [21], one (n = 390) in Nepal [15]
nd one (recruitment ongoing) in Australia [27].
Of the 16 studies, there were nine naïve study populations
15,20–26,29], three were naïve to serotypes 1, 4, 7F and NTHi
17,28,30], one was naïve to serotypes 3, 6A and 19A [16] and one
aïve to NTHi [27]. Two  populations were not naïve [18,19]. Dagan
18] approximated a 25% vaccine uptake in the population. van Gils’
009 [19] enrolment started on 7 July 2005, PCV7 was introduced
ationwide on 31 March 2006 and follow up ended 14 February
008. It was the author’s view that a herd effect was  unlikely to
ave interfered.
.3. Intervention
The vaccine formulation and valency varied across the included
tudies. Four studies compared two vaccines—PCV13 versus PCV7
16], PHiD-CV10 versus PCV7 [17], PHiD-CV10 versus PCV13
27] and Pnc-T versus Pnc-D versus placebo [26]. Seven studies
sed a pneumococcal vaccine with polysaccharides conjugated to
RM197. Five used a 7-valent vaccine [18–21,23] and two used a
-valent vaccine [24,25]. Five studies used a pneumococcal vaccine
ith the majority of polysaccharides conjugated to NTHi protein D;
our used PHiD-CV10 [15,28–30] and one used 11Pn-PD [22].conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-
typeable Haemophilus inﬂuenzae.
3.4. Outcomes
Nasopharyngeal carriage was  reported in all included studies.
The earliest NP swab age that provided data for each dose and each
outcome was used in the meta-analyses. For one versus zero doses,
NP swabs were taken at ∼4 months of age. For two  versus zero
dose, NP swabs were taken at ∼6 months of age. For three versus
zero doses, NP swabs were taken at ∼7 months of age.
We also assessed the adherence to WHO  recommendations for
pneumococcal carriage studies [13,14]. Thirteen studies collected
nasopharyngeal swabs [15–23,25–28], one collected pernasal
swabs [24] and two  were unclear [29,30]. Only ﬁve studies
used STGG for nasopharyngeal swab transport and storage media
[15,20,21,23,27], four used Amies [17–19,26] and one used Stewart
[16] transport media, three did not use transport media [22,24,25]
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Table 1
Characteristics of randomised controlled trials comparing the short-term impact of one, two and three primary doses of PCV on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus inﬂuenza.
Country Number
randomised for
carriage
Vaccine Schedule NP swab timinga Outcomes reported
from the RCTb,c
Which meta-analyses?
Hamaluba [15] Nepal 390 PHiD-CV10 2 + 1: 6,14 wk, 9 m
3  + 0: 6,10,14 wk
0 + 2: 10,11 m
9 m Immunogenicity, OPA,
safety, carriage (Spn O)
2 vs 0 (Spn Od)
3  vs 0 (Spn O)
Dagan  [16] Israel 1866 PCV13, PCV7 3 + 1: 2,4,6,12 m 2,4,6,7,12,13,18,24 m Immunogenicity,
safety, carriage (Spn
VT, NVT)
3 vs 0 (Spn VT)
van  den Bergh [17] Netherlands 780 PHiD-CV10, PCV7 3 + 1: 2,3,4,11–13 m 5,11,14,18,24 m Carriage (NTHi) 3 vs 0 (NTHi)
Dagan  [18] Israel 733 PCV7 2 + 1: 4,6,12 m
3  + 1: 2,4,6,12 m
0 + 2: 12,18 m
2,4,6,7,12,13,18,19,24,
30 m
Immunogenicity,
carriage (Spn O,  VT,
NVT)
1 vs 0 (Spn O,  VT, NVT)
2 vs 1 (Spn O, VT, NVT)
2 vs 0 (Spn O,  VT, NVT)
3 vs 2 (Spn O, VT, NVT)
3 vs 0 (Spn O,  VT, NVT)
van  Gils [19,31] Netherlands 1005 PCV7 Zero doses 2 + 0:
2,4 m
2 + 1: 2,4,11 m
6 wk, 6,12,18,24 m Immunogenicity, OPA,
carriage (Spn O,  NTHi)
2 vs 0 (Spn O)
Ota  [20] Gambia 684 PCV7 1 + PPV: 2,10 m
2 + PPV: 2,3,10 m
3 + PPV:2,3,4,10 m
2,5,11,15 m Safety,
immunogenicity, OPA,
carriage (Spn O,  VT,
NVT)
2 vs 1 (Spn O, VT, NVT)
3 vs 1 (Spn O, VT, NVT)
3 vs 2 (Spn O, VT, NVT)
Russell  [21,32] Fiji 552 PCV7 0 dose
1 + 0: 14 wk
2 + 0: 6,14 wk
3 + 0: 6,10,14 wk
Booster to 1/2 per
group
6,9,12,17 m Immunogenicity, OPA,
safety, carriage (Spn O,
VT, NVT)
1 vs 0 (Spn O,  VT, NVT)
2 vs 1 (Spn O, VT, NVT)
3 vs 1 (Spn O, VT, NVT)
2 vs 0 (Spn O,  VT, NVT)
3 vs 2 (Spn O, VT, NVT)
3 vs 0 (Spn O,  VT, NVT)
Prymula  [22,33] Czech Republic
and Slovakia
381 11Pn-PD, Hep A 3 + 1: 3,4,5,12–15 m 6,12–15,13–16,15–18,
19–22,24–27 m
Clinical,
immunogenicity, OPA,
safety, carriage (Spn O,
VT, NVT, NTHi)
3 vs 0 (Spn O,  VT, NVT)
3 vs 0 (NTHi)
O’Brien  [23,34] Navajo and
White
Mountain
Apache
reservations
566 PCV7, MnCC 3 + 1: 2,4,6,12–15 m 7,12,18 m Clinical, safety,
immunogenicity,
carriage (Spn O,  VT,
NVT)
3 vs 0 (Spn O,  VT, NVT)
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Obaro [24] Gambia 207 PCV9, IPV 3 + 0: 2,3,4 m 5, 9 m Safety,
immunogenicity,
carriage (Spn O, VT,
NVT)
3 vs 0 (Spn O,  VT, NVT)
Mbelle  [25] South Africa 500 PCV9, placebo 3 + 0: 6,10,14 wk 6,10,14,18 wk,  9 m Safety,
immunogenicity,
carriage (Spn O, VT,
NVT)
1 vs 0 (Spn O)  2 vs 0
(Spn O) 3 vs 0 (Spn O,
VT, NVT)
Dagan  1997 [26,35] Israel 75 Pnc-D, Pnc-T,
placebo
3 + 1: 2,4,6, 12 m
(non-conjugate
booster)
2,4,6,7,12,13 m Immunogenicity,
safety, carriage (Spn
VT, NVT)
3 vs 0 (Spn O,  VT, NVT)
Leach  (Menzies
data) [27]
Australia Recruitment
ongoing
PHiD-CV10, PCV13 PCV10: 2,4,6 m
PCV13: 2,4,6 m
Both: PCV10
1,2,4 m PCV13 6 m
2,4,6,7 m Unpublished carriage
(Spn O,  VT, NVT, NTHi)
1 vs 0 (Spn O,  VT, NVT)
1 vs 0 (NTHi)
2  vs 1 (Spn O, VT, NVT)
2 vs 1 (NTHi)
2  vs 0 (NTHi)
Madhi  (ESPID
abstract) [28]
South Africa 300 PHiD-CV10 2 + 1: 6,14 wk,
9–10 m
3 + 0: 6,10,14 wk
3 + 1: 6,10,14 wk,
9–10 m
6–12,18 wk,9–10,10–11,
12–13,15–18,16–19,24–27 m
Unpublished carriage
(Spn O,  VT)
3 vs 2 (Spn O, VT, NVT)
COMPAS  (Clinical
trials.gov)
[29,36]
Argentina,
Colombia,
Panama
Spn: 1628
NTHi: 1644
PHiD-CV10, HepB
(Hep A for control
booster)
3 + 1: 2,4,6,15–18 m 5, 10-13, 13-16, 14–17,
16-19, 22–25
Safety,
immunogenicity,
clinical, OPA,
unpublished carriage
(Spn VT, NVT, NTHi)
2 vs 0 (Spn O,  VT, NVT)
2 vs 0 (NTHi)
FinIP  Nested (GSK
Clinical Study
Register) [30,37]
Finland 5093
(6 wk–6 mth)
PHiD-CV10, HBV If enrolled
6 wk–6 m: 3 + 1,
2  + 1
3,6,11–12,14–15,18–22 m Immunogenicity,
clinical, safety, OPA,
unpublished carriage
(Spn O,  VT, NTHi)
2 vs 0 (Spn O,  VT, NVT)
2 vs 0 (NTHi)
3  vs 0 (Spn O,  VT, NVT)
3 vs 0 (NTHi)
a Bolded swab time-points indicate which swab data was  used for the meta-analyses.
b Outcomes listed were only those found in studies and databases during our search.
c Carriage outcomes listed are only for prevalence <12 months and serotype-speciﬁc carriage.
d Overall (O).
708 T.R. Nicholls et al. / Vaccine 34 (2016) 703–713
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rig. 2. A meta-analysis of randomised controlled trials comparing the short-term 
oses  on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable H
nd three were not stated [28–30]. Use of a calibrated inoculum size
or culture was reported by four studies [20,21,23,27]; eight stud-
es reported direct plating [16,18–20,22,24–26]. Selective media for
neumococcus (blood agar with gentamicin) was used by ten stud-
es [16,18–25,27] and incubation in up to 10% CO2 was  reported by
ight studies [15,16,19,21–24,27]. Good overall adherence to WHO
ecommendations was reported by four studies [20,21,23,27].t of one, two  and three primary doses of pneumococcal conjugate vaccine to zero
hilus inﬂuenzae.
3.5. Risk of bias within studies
Overall, the risk of bias within each study was  very low (Table 2).
Twelve studies [15–17,19–24,27,29,30] described appropriate ran-
dom sequence generation and four [18,25,26,28] were unclear
but deemed probably low risk of bias. Randomisation was lost in
O’Brien’s carriage subset [23] which was selected from clusters
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Table 2
Risk of bias assessment of randomised controlled trials comparing the short-term impact of one, two and three primary doses of pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and
non-typeable Haemophilus inﬂuenzae.
Random sequence
generation
Allocation
concealment
Blinding of participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Other sources
of  bias
Hamaluba [15] Low Low Not blinded probably low Low Low Low Low
Dagan  [16] Low Low Unclear probably low Unclear probably
low
Low Low Low
van  den Bergh [17] Low Low Not blinded probably low Low Low Low Low
Dagan  [18] Unclear probably
low
Unclear probably
low
Not blinded probably low Low Low Low Low
van  Gils [19,31] Low Unclear probably
low
Not blinded probably low Low Low Low Low
Ota  [20] Low Unclear probably
low
Not blinded probably low Low Low Low Low
Russell  [21,32] Low Low Not blinded probably low Low Low Low Low
Prymula [22,33] Low Unclear probably
low
Unclear probably low Unclear probably
low
Low Low Low
O’Brien  [23,34,38] Low for trial high
for carriage
Low Low Low Unclear probably
low
Low Low
Obaro  [24] Low Unclear probably
low
Low Unclear probably
low
Low Low Low
Mbelle  [25] Unclear probably
low
Unclear probably
low
Low Unclear probably
low
Low Low Low
Dagan  [26,35] Unclear probably
low
Low Low Low Low Low Low
Leach  (unpublished,
Menzies data) [27]
Low Low Not blinded probably low Low N/A N/A N/A
Madhi  abstract [28] Unclear probably
low
Unclear probably
low
Not blinded probably low Unclear probably
low
Low Low N/A
COMPAS (unpublished,
clinicaltrials.gov) [29,36]
Low Low Low Unclear probably
low
Unclear probably
low
Low Low
FinIP  (unpublished, GSK
clinical study register)
[30,37]
Low Low Low Low Low Low Low
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ccording to adherence to a per-protocol vaccination schedule.
e therefore performed a sensitivity analysis excluding this study
Supplementary Table 1). Allocation concealment was unclear in
even studies [18–20,22,24,25,28] but probably low risk. Nine
tudies [15–17,21,23,26,27,29,30] reported sound concealment of
llocation.
Six studies blinded participants and personnel [23–26,29,30],
ight studies were not blinded [15,17–21,27,28] and two  were
nclear, stating that they were double blind without further
etail [16,22]. For blinding of outcome assessment, ten studies
15,17–21,23,26,27,30] described masking of the laboratory staff
low risk of bias). Six studies [16,22,24,25,28,29] were unclear but
eemed probably low risk.
Follow-up of participants for nasopharyngeal swabs was  per-
ormed well and described appropriately in thirteen studies
15–22,24–26,28,30]. Two studies [23,29] were unclear but were
eemed probably low risk and one was not available [27]. As
or selective reporting, all studies reported according to protocol
r pre-speciﬁed outcomes [15–30]. Baseline characteristics were
eported in text or table in all studies except Madhi [28] and Leach
27] which were not available in the abstract or protocol, respec-
ively.
Eleven studies were funded by drug companies
15–19,22,23,25,28–30]. Four studies were not funded by drug
ompanies [20,21,24,27], two of whom received vaccine donations
20,21]. One study did not report funding source [26].
.6. Risk of bias across studies
The funnel plots generated did not indicate a difference between
he reporting of small and large studies (Supplementary Fig. 1).
.7. Results of individual studies
Prior to pooling data in the meta-analyses, we applied our data
xtraction rules. We  used the COMPAS swab data at 5 months of age
ut excluded data at 10–13 months [29], since our inclusion criteria
ere that swabs be collected at <12 months of age. We  selected the
utcome data at 7 months of age from Dagan’s [18] combined 7 + 12
onth data, using a provided dataset. Data from 4 and 6 month
wabs were also extracted from this dataset. In Dagan [26], the
umerator and denominator were not reported for 2, 4 & 6 month
revalence data so we were only able to include the outcomes at
 months of age. In Dagan [16], cross-protective serotypes were
ncluded as vaccine types.
For our RCT [27] which is still recruiting, we analysed the avail-
ble 2 and 4 month NP carriage data. To maintain blinding, only
ggregate data for each scheduled visit and allocated group were
rovided to authors by the data manager.
The relative risks for individual studies and dose comparisons
re presented in the meta-analyses (Figs. 2 and 3).
.8. Syntheses of results
We  generated meta-analyses comparing the short-term impact
f one, two and three doses of PCV with zero doses (Fig. 2) and
omparing more doses with fewer doses (Fig. 3) on nasopharyn-
eal carriage. We  used the earliest swab data reported for each
omparison.
The meta-analyses comparing one versus zero doses (Fig. 2) gen-
rated non-signiﬁcant pooled results for overall pneumococcus, VT
neumococcus and NTHi carriage at ∼4 months but signiﬁcantly
igher relative risk of NVT pneumococcal carriage RR 1.36 95%CI
.08–1.72 from 3 studies and 1000 infants swabbed. A single study
ontributed data to the NTHi carriage comparison RR 0.77 95%CI
.57–1.04 from 234 infants swabbed 34 (2016) 703–713
The meta-analyses comparing two  versus zero doses (Fig. 2)
generated non-signiﬁcant pooled results for pneumococcal and
NTHi outcomes at ∼6 months.
The meta-analyses comparing three versus zero doses (Fig. 2)
generated signiﬁcant pooled results for VT pneumococcal carriage
at ∼7 months RR 0.67 95%CI 0.56–0.81 from 9 studies and 7613
infants swabbed and non-vaccine type pneumococcal carriage RR
1.23 95%CI 1.09–1.40 from 8 studies and 5861 infants swabbed.
However, NTHi carriage was  not signiﬁcantly different RR 1.13
95%CI 0.95–1.35 from 3 studies and 4843 infants swabbed.
The meta-analyses comparing more with fewer doses (Fig. 3)
generated non-signiﬁcant pooled results for all carriage outcomes
from 4 to 7 months. The three dose schedule had a reduced risk of
VT carriage compared to both the one and two-dose schedules, but
the reductions did not reach statistical signiﬁcance RR 0.73 95%CI
0.51–1.06 and RR 0.81 95%CI 0.64–1.02 from 2 studies and 681
infants swabbed and 4 studies and 1333 infants swabbed respec-
tively. The two-dose schedule had a reduced risk of VT carriage
compared to one dose, but did not reach statistical signiﬁcance RR
0.86 95%CI 0.66–1.13 from 4 studies and 1188 infants swabbed. The
relative risk of NVT pneumococcal carriage was not signiﬁcantly
increased for any of these comparisons. NTHi carriage was reduced
following a two-dose schedule compared to a single dose RR 0.82
95%CI 0.63–1.07 from 1 study and 147 infants swabbed, but this did
not reach statistical signiﬁcance.
Within each meta-analysis, clinical heterogeneity was related
to; population naivety to PCV, vaccine formulation, NP swab age
and NP swab collection method. However, statistical heterogene-
ity was <50% for all meta-analyses except one; the three versus
zero dose comparison of VT pneumococcal carriage meta-analysis
(Fig. 2) which generated an I2 of 52.1% from 9 studies with 7613
infants swabbed.
3.9. Sensitivity analyses
The sensitivity analyses excluding O’Brien [23] from the three
versus zero dose meta-analyses (overall, VT and NVT pneumococcal
carriage) showed no substantial difference to the original relative
risks or conﬁdence intervals (Supplementary Table 1).
4. Discussion
To determine the potential for PCVs to reduce early-onset
polymicrobial otitis media, we  assessed the direct and short-term
impact of each dose of primary PCV schedules on NP carriage of Spn
and NTHi.
Our ﬁndings are consistent with previous systematic reviews
for the impact of PCV on NP carriage [9–11]. However, our review
includes an additional seven RCTs, is the ﬁrst to include a single
dose comparison and the ﬁrst to include NTHi carriage. We  sta-
tistically combined our results with meta-analysis and identiﬁed
several new ﬁndings for the short-term effect of PCVs on NP car-
riage of Spn and NTHi following each dose of the primary schedule
in infancy.
We found that three doses of PCV was the only dosing schedule
to signiﬁcantly reduce VT pneumococcal carriage when compared
to no PCV. More doses were consistently superior to fewer doses
and although these differences did not reach statistical signiﬁcance,
they reﬂect a dose response that could be clinically useful.
NVT pneumococcal carriage (replacement) was signiﬁcant after
one and three doses of vaccine and the point estimate for the two-
dose comparison was not inconsistent with this.NTHi carriage was also not signiﬁcantly reduced by primary
vaccination with HiD-containing vaccines. Compared to no HiD
controls, NTHi carriage was lower following a single dose (one
study), was  not different follow two doses (three studies) and was
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ncreased following three doses (three studies). This observation
hat NTHi NP carriage is increased following a three-dose schedule
ompared to no dose is potentially concerning. Although statis-
ically non-signiﬁcant, the point prevalence for each of the three
tudies showed the same trend. Interestingly, the one versus zero
ose and two versus one-dose comparisons showed lower NTHi
arriage with more doses. More data on NTHi carriage would assist
n clarifying these trends.
Fleming-Dutra’s review [9] concluded that both 2 and 3 dose
rimary schedules reduced VT pneumococcal carriage compared to
ero doses. When directly comparing VT carriage post two to three
rimary doses, Fleming-Dutra found three trials with pre-booster
omparisons [18,20,21], of which one [21] found a signiﬁcant dif-
erence at 9 months of age. Scott’s review [10] found no signiﬁcant
ifference at 6 months between two and three doses for overall, VT
r NVT pneumococcal carriage..1. Limitations
We  found few studies that reported NTHi carriage data
r reported data following a single dose. Adherence to WHOact of different primary schedules on nasopharyngeal carriage of Streptococcus
recommendations for NP carriage was also poor across studies. We
used unpublished, non-peer reviewed data for ﬁve of our included
studies [18,27–30]. Within included studies, the overall risk of
bias was  very low, the sensitivity analyses did not substantially
change the effect size and no evidence of small study bias was
found. While there was a degree of clinical heterogeneity within
each meta-analysis, the statistical heterogeneity was generally
low.
4.2. Implications for research
RCTs evaluating NP carriage are encouraged to publish ﬁnd-
ings following each dose of PCV, particularly for high risk settings.
Future trials should investigate an earlier vaccine schedule. Scott
[39] found no signiﬁcant difference between a 6–10–14 wk and
0–10–14 wk  schedule at 18 or 36 weeks, differences at earlier ages
were not reported. We  are awaiting publication of the carriage out-
comes from Pomat’s 2013 birth dose trial from Papua New Guinea
(completed and manuscript in preparation) [40]. Maternal vaccina-
tion could also be further investigated. Binks et al. [41] showed that
maternal 23-valent pneumococcal polysaccharide vaccine (23PPV)
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id not reduce prevalence of all-cause otitis media in Aboriginal
nfants at age 7 months, but a post-hoc analysis found that otitis
edia associated with NP carriage of several 23PPV serotypes was
educed in the vaccinated cohort compared to non-vaccinated. In
 recently published study, Daly 2014, maternal PCV9 vaccination
ncreased the infant risk of acute otitis media in the ﬁrst 6 months
f life [42]. Carriage outcomes were not assessed. We  suggest that
urther research on social determinants, particularly overcrowding
nd hygiene will be important to understanding how best to reduce
athogen transmission and early NP carriage.
Ecological studies that have compared NP carriage before and
fter introduction of PHiD-CV10 into the national immunisation
rograms have had inconsistent ﬁndings. In Kenya [43] a signif-
cant reduction in NTHi carriage was reported. In the Northern
erritory of Australia no signiﬁcant impact on NTHi carriage was
ound, although signiﬁcantly fewer PHiD-CV10-vaccinated chil-
ren had NTHi cultured from middle ear infections compared to
CV7-vaccinated children [44]. A lack of impact on NTHi carriage
ontrasts with immunogenicity data for H. inﬂuenzae protein D
ne month after the third dose of primary vaccination [29]. More
esearch is needed to determine appropriate (immune) correlates
f protection for NTHi (and other) protein antigens.
.3. Implications for practice
Based on our ﬁndings, in a high risk population naïve to PCVs
if we assume carriage ∼80% with 1/2 VTs), three primary doses
f PCV would reduce VT pneumococcal carriage from ∼40% to
7% and increase NVT carriage from ∼40% to 50% at ∼7 months
f age. This means that overall carriage would fall from ∼80% to
7%. This is unlikely to have a clinical impact unless NVTs are less
irulent in causing disease. A less expensive single-dose or two-
ose schedule is unlikely to affect nasopharyngeal colonisation
ithin this short time frame. However, small reductions may  have
 cumulative effect over time and as indirect effects accumulate as
accine uptake increases. With a longer follow up period of 9–12
onths, two of our included trials found that a signiﬁcant protec-
ion occurred for VT pneumococcal carriage after one dose RR 0.38
5%CI 0.16–0.91 at 9 months [21] and two doses RR 0.64 95%CI
.51–0.81 at 12 months [31]. This will be important for sustained
rotection throughout infancy.
In our setting, we are most concerned by early-onset otitis
edia. By the time Aboriginal infants reach ∼7 months of age, when
he third primary dose will offer protection for NP carriage, most
re already colonised and affected by otitis media. Multiple cross-
ectional studies have demonstrated that herd immunity does
ccur and this may  help to protect young infants [45]. However, to
ubstantially reduce the burden of early-onset otitis media–each
ose of the primary PCV schedule needs to have a direct impact on
P carriage prevention, particularly where herd effects are absent
r weak, such as for NTHi [17]. Our ﬁndings will be important for
he evaluation of future vaccines and their application in high-risk
ettings.
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